Stabilized liquid anti-RSV antibody formulations
View Patent ↗The present invention provides liquid formulations of SYNAGIS® or an antigen-binding fragment thereof that immunospecifically bind to a respiratory syncytial virus (RSV) antigen, which formulations exhibit stability, low to undetectable levels of aggregation, and very little to no loss of the biological activities of SYNAGIS® or an antigen-binding fragment thereof, even during long periods of storage. In particular, the present invention provides liquid formulations of SYNAGIS® or an antigen-binding fragment thereof which immunospecifically binds to a RSV antigen, which formulations are substantially free of surfactant, inorganic salts, and/or other common excipients. Furthermore, the invention provides method of preventing, treating or ameliorating symptoms associated with RSV infection utilizing liquid formulations of the present invention.
1. An aqueous palivizumab formulation comprising, in an aqueous carrier: (a) at least 75 mg/ml of palivizumab, or an antigen-binding fragment thereof; and (b) histidine, wherein said palivizumab or palivizumab antigen-binding fragment in the formulation is stable at 2° C. to 8° C. for at least 15 months as determined by high performance size exclusion chromatography (HPSEC).
2. An aqueous palivizumab formulation comprising, in an aqueous carrier: (a) at least 75 mg/ml of palivizumab, or an antigen-binding fragment thereof; and (b) histidine, wherein said formulation does not comprise mannitol, and wherein said palivizumab or palivizumab antigen-binding fragment in the formulation is stable at 2° C. to 8° C. for at least 15 months as determined by HPSEC.
3. The formulation of claim 1 or 2 , wherein said palivizumab or palivizumab antigen-binding fragment is at a concentration of about 80 mg/ ml.
4. The formulation of claim 1 or 2 , wherein said palivizumab or palivizumab antigen-binding fragment is at a concentration of at least 80 mg/ml.
5. The formulation of claim 1 or 2 , wherein said palivizumab or palivizumab antigen-binding fragment is at a concentration of at least 85 mg/ml at least 90 mg/ml or at least 95 mg/ml.
6. The formulation of claim 1 or 2 , wherein the histidine is at a concentration of 1 mM to 100 mM or 10 mM to 50 mM.
7. The formulation of claim 1 or 2 , wherein the histidine is at a concentration of 20 mM to 30 mM.
8. The formulation of claim 1 or 2 , wherein said formulation comprises an excipient other than a surfactant.
9. The formulation of claim 8 , wherein the excipient is glycine.
10. The formulation of claim 9 , wherein the glycine is at a concentration of less than 150 mM, less than 100 mM, or less than 50 mM.
11. The formulation of claim 9 , wherein the glycine is at a concentration of less than 3 mM or less than 2 mM.
12. The formulation of claim 1 or 2 , wherein said formulation is substantially free of surfactants and inorganic salts.
13. The formulation of claim 3 , wherein said formulation is substantially free of surfactants, inorganic salts and other excipients.
14. The formulation of claim 1 or 2 , wherein said formulation has a pH of between about 5.5 to about 7.0.
15. The formulation of claim 1 or 2 , wherein said formulation has a pH of between about 5.5 to about 6.5.
16. The formulation of claim 1 or 2 , wherein said palivizumab or palivizumab antigen-binding fragment in the formulation is stable at 20° C. to 24° C. temperature for at least 1 year as determined by HPSEC.
17. The formulation of claim 1 or 2 , wherein said aqueous carrier is distilled water.
18. The formulation of claim 1 or 2 , wherein said formulation is sterile.
19. The formulation of claim 1 or 2 , wherein said palivizumab or palivizumab antigen-binding fragment is conjugated to a therapeutic moiety.
20. The formulation of claim 1 or 2 , wherein said palivizumab or palivizumab antigen-binding fragment is conjugated to a detectable substance.
21. A pharmaceutical unit dosage comprising the formulation of claim 1 or 2 , which dosage is suitable for administration to a human and is in a suitable container.
22. A sealed container comprising the formulation of claim 1 or 2 .
23. An aqueous palivizumab formulation comprising, in an aqueous carrier: (a) at least 75 mg/ml of palivizumab, or an antigen-binding fragment thereof; (b) histidine at a concentration of 23 mM to 27 mM; and (c) glycine at a concentration of less than 2 mM, wherein said formulation has a pH of between about 5.5 to 6.5, and wherein said palivizumab or palivizumab antigen-binding fragment in the formulation is stable at 2° C. to 8° C. for at least 15 months as determined by HPSEC.
24. The formulation of claim 23 , wherein histidine is at a concentration of 25 mM.
25. The formulation of claim 23 or 24 , wherein glycine is at a concentration of 1.6 mM.
26. The formulation of claim 23 , wherein said formulation has a pH of about 6.0.
27. The formulation of claim 26 , wherein histidine is a concentration of 25 mM and glycine is a concentration of 1.6 mM.
28. The formulation of claim 23 , wherein said palivizumab or palivizumab antigen-binding fragment is at a concentration of about 80 mg/ml.
29. The formulation of claim 27 , wherein said palivizumab or palivizumab antigen-binding fragment is at a concentration of about 80 mg/ml.
30. The formulation of claim 23 , wherein said palivizumab or palivizumab antigen-binding fragment is at a concentration of at least 80 mg/ml.
31. The formulation of claim 27 , wherein said palivizumab or palivizumab antigen-binding fragment is at a concentration of at least 80 mg/ml.
32. The formulation of claim 23 or 27 , wherein said palivizumab or palivizumab antigen-binding fragment is at a concentration of at least 85 mg/ml, at least 90 mg/ml or at least 95 mg/ml.
33. The formulation of claim 23 , 28 or 30 , wherein said formulation is substantially free of surfactants, inorganic salts and other excipients.
34. The formulation of claim 27 , 29 or 31 , wherein said formulation is substantially free of surfactants, inorganic salts and other excipients.
35. The formulation of claim 23 , 28 or 30 , wherein said aqueous carrier is distilled water.
36. The formulation of claim 27 , 29 or 31 , wherein said aqueous carrier is distilled water.
37. The formulation of claim 34 , wherein said aqueous carrier is distilled water.
38. The formulation of claim 23 , 28 or 30 , wherein said formulation is sterile,
39. The formulation of claim 27 , 29 or 31 , wherein said formulation is sterile.
40. The formulation of claim 37 , wherein said formulation is sterile.
41. The formulation of claim 23 or 27 , wherein said palivizumab or palivizumab antigen-binding fragment is conjugated to a therapeutic moiety.
42. The formulation of claim 23 or 27 wherein said palivizumab or palivizumab antigen-binding fragment is conjugated to a detectable agent.
43. A pharmaceutical unit dosage form comprising the formulation of claim 23 , 28 or 30 , which dosage form is suitable for administration to a human and is in a suitable container.
44. A pharmaceutical unit dosage comprising the formulation of claim 27 , 29 or 31 , which dosage is suitable for administration to a human and is in a suitable container.
45. A sealed container comprising an aqueous palivizumab formulation, wherein said formulation comprises 100 mg/ml of palivizumab or a palivizumab antigen-binding fragment, about 25 mM histidine, and about 1.6 mM glycine in 1.2 ml of distilled water, and wherein said palivizumab or palivizumab antigen-binding fragment in the formulation is stable at 2° C. to 8° C. for at least 15 months as determined by HPSEC.
46. A sealed container comprising an aqueous palivizumab formulation, wherein said formulation: (a) comprises 100 m/l of palivizumab or a palivizumab antigen-binding fragment, about 25 mM histidine, and about 1.6 mM glycine in 1.2 ml of distilled water; and (b) does not comprise mannitol, and wherein said palivizumab or palivizumab antigen-binding fragment in the formulation is stable at 2° C. to 8° C. for at least 15 months as determined by HPSEC.
47. The sealed container of claim 45 or 46 , wherein said palivizumab or palivizumab antigen-binding fragment in the formulation is stable at 2° C. to 8° C. for 15 months as determined by HPSEC.
48. The sealed container of claim 45 or 46 , wherein said palivizumab or palivizumab antigen-binding fragment in the formulation is stable at 2° C. to 8° C. for at least 3 years as determined by HPSEC.
49. The sealed container of claim 45 or 46 , wherein said palivizumab or palivizumab antigen-binding fragment in the formulation is stable at 20° C. to 24° C. for at least 1 year.
50. The sealed container of claim 45 or 46 , wherein the aqueous palivizumab formulation contains no more than 3% aggregation by weight protein as measured by HPSEC.
51. The scaled container of claim 45 or 46 , wherein the stable aqueous palivizumab formulation contains equal to or more than 98% of the total protein in a single peak as determined by HSPEC and contains no other single peaks having more than 2% of total protein each.
52. The formulation of claim 1 or 2 , wherein said palivizumab or palivizumab antigen-binding fragment in the formulation is stable at 2° C. to 8° C. for 15 months as determined by HPSEC.
53. The formulation of claim 1 or 2 , wherein said palivizumab or palivizumab antigen-binding fragment in the formulation is stable at 2° C. to 8° C. for at least 3 years as determined by HPSEC.
54. The formulation of claim 1 or 2 which contains no more than 3% aggregation by weight protein as measured by HPSEC.
55. The formulation of claim 1 or 2 which contains equal to or more than 98% of the total protein in a single peak as determined by HSPEC and contains no other single peaks having more than 2% of total protein each.
56. The formulation of claim 23 or 27 , wherein said palivizumab or palivizumab antigen-binding fragment in the formulation is stable at 2° C. to 8° C. for 15 months as determined by HPSEC.
57. The formulation of claim 23 or 27 , wherein said palivizumab or palivizumab antigen-binding fragment in the formulation is stable at 2° C. to 8° C. for at least 3 years as determined by HPSEC.
58. The formulation of claim 23 or 27 , wherein said palivizumab or palivizumab antigen-binding fragment in the formulation is stable at 20° C. to 24° C. for at least 1 year.
59. The formulation of claim 23 or 27 which contains no more than aggregation by weight protein as measured by HPSEC.
60. The formulation of claim 23 or 27 which contains equal to or more than 98% of the total protein in a single peak as determined by HSPEC and contains no other single peaks having inure than 2% of total protein each.
61. An aqueous palivizumab formulation comprising, in an aqueous carrier: (a) at least 75 mg/ml of palivizumab, or an antigen-binding fragment thereof; (b) histidine at a concentration of 23 mM to 27 mM; and (c) glycine at a concentration of less than 2 mM, wherein said formulation has a pH of between about 5.5 to 6.5 and does not comprise mannitol, and wherein said palivizumab or palivizumab antigen-binding fragment in the formulation is stable at 2° C. to 8° C. for at least 15 months as determined by HPSEC.
62. The formulation of claim 61 , wherein histidine is at a concentration of 25 mM.
63. The formulation of claim 61 or 62 , wherein glycine is at a concentration of 1.6 mM.
64. The formulation of claim 61 , wherein said formulation has a pH of about 6.0.
65. The formulation of claim 64 , wherein histidine is a concentration of 25 mM and glycine is a concentration of 1.6 mM.
66. The formulation of claim 61 , wherein said palivizumab or palivizumab antigen-binding fragment is at a concentration of about 80 mg/ml.
67. The formulation of claim 65 , wherein said palivizumab or palivizumab antigen-binding fragment is at a concentration of about 80 mg/ml.
68. The formulation of claim 61 , wherein said palivizumab or palivizumab antigen-binding fragment is at a concentration of at least 80 mg/ml.
69. The formulation of claim 65 , wherein said palivizumab or palivizumab antigen-binding fragment is at a concentration of at least 80 mg/ml.
70. The formulation of claim 61 or 65 , wherein said palivizumab or palivizumab antigen-binding fragment is at a concentration of at least 85 mg/ml, at least 90 mg/ml or at least 95 mg/ml.
71. The formulation of claim 61 , 62 or 66 wherein said formulation is substantially free of surfactants, inorganic salts and other excipients.
72. The formulation of claim 65 , 67 or 69 , wherein said formulation is substantially free of surfactants, inorganic salts and other excipients.
73. The formulation of claim 61 , 62 or 66 , wherein said aqueous carrier is distilled water.
74. The formulation of claim 65 , 67 or 69 , wherein said aqueous carrier is distilled water.
75. The formulation of claim 72 , wherein said aqueous carrier is distilled water.
76. The formulation of claim 61 , 62 or 66 , wherein said formulation is sterile.
77. The formulation of claim 65 , 67 or 69 , wherein said formulation is sterile.
78. The formulation of claim 75 , wherein said formulation is sterile.
79. The formulation of claim 61 or 65 , wherein said palivizumab or palivizumab antigen-binding fragment is conjugated to a therapeutic moiety.
80. The formulation of claim 61 or 65 , wherein said palivizumab or palivizumab antigen-binding fragment is conjugated to a detectable agent.
81. A pharmaceutical unit dosage form comprising the formulation of claim 61 , 62 or 66 , which dosage form is suitable for administration to a human and is in a suitable container,
82. A pharmaceutical unit dosage comprising the formulation of claim 65 , 67 or 69 , which dosage is suitable for administration to a human and is in a suitable container.